ROCHESTER, N.Y., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announced it will be presenting both a poster and a podium session at the International Cancer Immunotherapy Conference.  The conference is co-sponsored by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR).

The title for both sessions is “Reprogramming myeloid cells in TME with first-in-class semaphorin 4D MAb enhances combination immunotherapy.”  The poster will be shown on Sunday, September 30, 2018 from 11:45 AM – 2:15 PM ET.  Subsequently, the company will be part of a podium session on Tuesday, October 2, 2018 during Session 5, “Novel Vaccine Platforms and Combinations,” from 12:30 – 12:45 PM ET. The conference will be held from September 30 – October 3, 2018 at the New York Marriott Marquis in New York City.

About Vaccinex, Inc. 

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in Rochester, New York. 

About the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) are proud to once again join forces to present the International Cancer Immunotherapy Conference. The program will focus on “Translating Science into Survival” and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy. This meeting will provide an unparalleled opportunity for teaching, learning, and networking among all stakeholders in the field: scientists, clinicians, regulators, drug developers, and patient advocates. 

Investor Contact

Michael Rice
LifeSci Advisors, LLC
Phone: (646) 597-6979
E-mail: mrice@lifesciadvisors.com

Media Contact

Jules Abraham
JQA Partners, Inc.
Phone: (917) 885-7378
E-mail: jabraham@jqapartners.com